Study: NCT02951845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Oral Suspension)
Description: Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Oral Suspension)
Description: Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Oral Suspension)
Description: Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Oral Suspension)
Description: Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Oral Suspension)
Description: Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Oral Suspension)
Description: Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Oral Suspension)
Description: Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Oral Suspension)
Description: Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Oral Suspension)
Description: Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Oral Suspension)
Description: Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Oral Suspension)
Description: Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Oral Suspension)
Description: Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Formulation 1: Direct Compression Tablets)
Description: Participants will receive JNJ-54416076 Tablet formulation 1 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Formulation 1: Direct Compression Tablets)
Description: Participants will receive JNJ-54416076 Tablet formulation 1 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Formulation 1: Direct Compression Tablets)
Description: Participants will receive JNJ-54416076 Tablet formulation 1 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Formulation 1: Direct Compression Tablets)
Description: Participants will receive JNJ-54416076 Tablet formulation 1 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Formulation 1: Direct Compression Tablets)
Description: Participants will receive JNJ-54416076 Tablet formulation 1 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Formulation 1: Direct Compression Tablets)
Description: Participants will receive JNJ-54416076 Tablet formulation 1 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Formulation 2: Fluid Bed Granulation Tablets)
Description: Participants will receive JNJ-54416076 Tablet formulation 2 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Formulation 2: Fluid Bed Granulation Tablets)
Description: Participants will receive JNJ-54416076 Tablet formulation 2 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Formulation 2: Fluid Bed Granulation Tablets)
Description: Participants will receive JNJ-54416076 Tablet formulation 2 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Formulation 2: Fluid Bed Granulation Tablets)
Description: Participants will receive JNJ-54416076 Tablet formulation 2 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Formulation 2: Fluid Bed Granulation Tablets)
Description: Participants will receive JNJ-54416076 Tablet formulation 2 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076 (Formulation 2: Fluid Bed Granulation Tablets)
Description: Participants will receive JNJ-54416076 Tablet formulation 2 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 2.